The company defends its cancer strategy, and says it's not a me-too developer.

The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.

Supply continues to cause headaches for radiopharmaceutical developers.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.

A Car-T therapy to which Astra has rights has wowed in a solid tumour after others had disappointed.